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ABSTRACT
Dominant mutations in the rhodopsin gene, which is
expressed in rod photoreceptor cells, are a major
cause of the hereditary-blinding disease, autosomal
dominant retinitis pigmentosa. Therapeutic strate-
gies designed to edit such mutations will likely
depend on the introduction of double-strand
breaks and their subsequent repair by homologous
recombination or non-homologous end joining. At
present, the break repair capabilities of mature
neurons, in general, and rod cells, in particular, are
undefined. To detect break repair, we generated
mice that carry a modified human rhodopsin-GFP
fusion gene at the normal mouse rhodopsin locus.
The rhodopsin-GFP gene carries tandem copies of
exon 2, with an ISceI recognition site situated
between them. An ISceI-induced break can be
repaired either by non-homologous end joining or
by recombination between the duplicated segments,
generating a functional rhodopsin-GFP gene. We
introduced breaks using recombinant adeno-
associated virus to transduce the gene encoding
ISceI nuclease. We found that virtually 100% of
transduced rod cells were mutated at the ISceI
site, with  85% of the genomes altered by end
joining and  15% by the single-strand anneal-
ing pathway of homologous recombination. These
studies establish that the genomes of terminally
differentiated rod cells can be efficiently edited in
living organisms.
INTRODUCTION
Defects in the rhodopsin gene cause the most common
form of the most common hereditary blinding disease,
retinitis pigmentosa (RP) (1,2). RP is a progressive
neurodegenerative disorder that begins with the death of
rod photoreceptors, where rhodopsin is expressed, but
ultimately destroys rod and cone cells, leading to loss of
both dim-light and color vision. All but a handful of the
more than 100 rhodopsin alleles that cause retinal degen-
eration display dominant inheritance (1,2). It is clear that
dominance arises from the harmful effects of mutant rhod-
opsin, rather than from a lack of adequate protein levels,
since human patients heterozygous for rare, null alleles of
the rhodopsin gene and mice with one knockout allele do
not suffer from serious degeneration (3–5). Thus, it is the
presence of rhodopsin encoded by the dominant allele that
leads to degeneration, although it remains an open
question whether its deleterious consequences are due to
toxic gain-of-function or interfering dominant-negative
effects (6). In either case, correcting the defective allele,
or knocking it out, would be expected to preserve retinal
function by diminishing the loss of rod cells, which in turn
would protect cones and extend the useful lifetime of
central vision.
A promising general strategy for editing the genome in
living cells is to introduce a double-strand break (DSB)
into the target gene and exploit the normal cellular DSB
repair processes to bring about the desired change (7–11).
Repair of the break by homologous recombination (HR),
in the presence of a non-mutant segment of DNA to act as
the template for repair, can correct the mutation (11).
Alternatively, repair by non-homologous end joining
(NHEJ), which is usually mutagenic, can knockout gene
expression (12). Although HR and NHEJ have been well-
deﬁned in cycling mammalian cells (13), their character-
ization in mature neurons, which no longer divide, is in its
infancy (14). At present, it is uncertain whether terminally
differentiated rod photoreceptor neurons possess the
requisite capabilities for DSB-dependent genome editing.
It is clear that the developing nervous system is exquis-
itely sensitive to DSBs, and that DSB repair by HR and
NHEJ is critical to prevent cell death by apoptosis (15).
Defects in either repair pathway, or the signaling
pathways that control them, can lead to neurological de-
fects and disease in humans and mouse models (15–17).
For example, mutations in the ATM gene in humans lead
to defects in the signaling response to DSBs, which causes
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disease that compromises the function of the cerebellum.
Although HR and NHEJ play important roles in the pro-
liferation and early stages of differentiation of the nervous
system, their contribution to genome maintenance in the
mature nervous system is poorly deﬁned (14). Because ter-
minally differentiated, non-dividing nerve cells in the
brain are mixed with a comparable number of glial cells
that retain mitotic capability, analysis of DSB repair in
neurons is inherently challenging. However, extracts from
unfractionated and neuron-enriched rat brain samples
display NHEJ activity, which declines with age (18,19).
These studies suggest that the NHEJ pathway of DSB
repair is probably functional in mature neurons.
Studies in cycling cells, the source of virtually all our
detailed information on DSB repair in mammalian cells,
indicate that HR functions primarily in the S and G2
phases of the cell cycle, when a sister chromatid—the
preferred template for HR repair—is available (20–22).
Since neurons are trapped in G1/G0, it is unclear a
priori whether HR is a viable strategy for modifying the
rhodopsin gene in rod photoreceptors. The block to HR
in G1 in cycling cells appears to be enforced at the step of
50 to 30 resection of the ends, which is required to expose
the single-stranded DNA needed for the strand-invasion
step in HR (23–25). In contrast, end resection is not
needed for NHEJ, which operates throughout the cell
cycle (13,20–22).
These considerations led us to expect that DSBs in rod
photoreceptor cells would likely be repaired predominant-
ly by mutagenic NHEJ and rarely, if at all, by HR. Thus,
we designed a mouse model that would allow us to detect
common NHEJ events by PCR-based methods and rare
HR events by an exquisitely sensitive ﬂuorescent assay
that is capable of providing a reliable readout for one or
a few events per retina (26,27). To detect HR repair of
DSBs, we replaced one mouse rhodopsin gene with a
modiﬁed form of the human rhodopsin gene fused to
enhanced GFP (26). This modiﬁed rhodopsin-GFP gene
carries two copies of exon 2, which ﬂank the recognition
sequence for the rare-cutting nuclease, ISceI. The dupli-
cate copy of exon 2 shifts the reading frame so that
rhodopsin-GFP is not expressed. Break-induced recom-
bination between the duplicated segments will reconstitute
a functional rhodopsin-GFP gene, giving rise to a bright
ﬂuorescent green outer segment on each corrected rod cell.
This recombination substrate is expected to generate green
rods by the single-strand annealing (SSA) pathway of HR.
SSA, like the Rad51-mediated strand-invasion pathway of
HR, begins by resection of ends at a DSB, but completes
the repair event by pairing the exposed, single strands
at complementary regions, thereby bypassing strand inva-
sion. Thus, by assaying for the SSA pathway of HR, this
duplication substrate tests whether end resection occurs
during DSB repair in rod cells, which is a prerequisite
for genome editing by HR.
Using recombinant adeno-associated virus (rAAV) to
introduce the ISceI gene, we addressed three questions
about DSBs in terminally differentiated rod photoreceptor
neurons. Can DSBs be efﬁciently introduced into the
rhodopsin gene? Can NHEJ and SSA repair DSBs in
rod cells? And if so, what are their relative frequencies?
Here, we show that most, if not all, rAAV-transduced rod
cells were cleaved at the target site, with 85% of the DSBs
repaired by NHEJ and 15% by SSA. The high frequency
of DSB repair by mutagenic NHEJ lays the foundation for
plausible therapeutic strategies designed to treat RP by
knocking out dominant rhodopsin alleles in rod cells in
patients. The surprisingly high frequency of DSB repair by
SSA indicates that end resection is unlikely to block HR in
rod cell neurons, raising the possibility that correction of
mutant rhodopsin alleles by HR may also be achievable.
Collectively, these results establish that the genomes of
terminally differentiated rod photoreceptor neurons can
be efﬁciently edited in living organisms.
MATERIALS AND METHODS
Generation of ID2-hRho-GFP knockin mice
All animal procedures were carried out according to
protocols approved by the Baylor College of Medicine
Institutional Animal Care and Use Committee, and in ac-
cordance with the Statement for the Use of Animals in
Ophthalmic and Visual Research of the Association for
Research in Vision and Ophthalmology. Knockin mice
were generated by gene targeting in HPRT-negative em-
bryonic stem (ES) cells. To make the targeting vector, we
modiﬁed a previously described segmental replacement
vector (26), which carried the human rhodopsin-GFP
fusion gene ﬂanked by LoxP and Lox511 sites, by insert-
ing a duplicate copy of exon 2 generated by PCR. The
PCR ampliﬁed segment comprised 613bp of rhodopsin
sequences, which included exon 2 along with 282bp and
162bp of 50- and 30-ﬂanking sequences, respectively, and
carried an EcoRV site and an ISceI site at its 50-end and an
EcoRV site at its 30-end. We inserted this PCR segment
706-bp downstream of the endogenous exon 2 into an
artiﬁcial EcoRV site that was made by point mutation
(AATATC to GATATC) to generate the
ID2-hRho-GFP gene. To construct the gene-targeting
vector, we excised the 8-kb ID2-hRho-GFP gene from
its plasmid by NotI digestion and cloned it into the
NotI site at 30-end of the HPRT minigene in the ﬁrst-step
targeting vector described previously (26). This cloning
step generates a vector that contains the ID2-hRho-GFP
gene adjacent to a LoxP-ﬂanked HPRT minigene, with
4.1kb of upstream and 6.5kb of downstream sequences
from the mouse rhodopsin locus (Figure 1A). We attached
the herpes virus TK gene to one end of the construct to
allow selection against random integrants. The targeting
vector contains a pBluescriptSK plasmid backbone.
We modiﬁed the rhodopsin locus in the HPRT-negative
ES cell line AB2.2 123, which was derived from mouse
strain 129SvEv, by HR so that the endogenous mouse
rhodopsin gene was replaced by an 11.9-kb
Sac1–HindIII fragment containing the LoxP-ﬂanked
HPRT minigene linked to the ID2-hRho-GFP gene
(Figure 1A). The Darwin Transgenic Core Facility,
Baylor College of Medicine, electroporated ES cells in
the presence of 15mg linearized targeting vector, and
grew the treated cells on mitomycin C inactivated SNLP
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was applied after 24h by growth in HAT
medium (0.1mM hypoxanthine/0.4mM aminopterin/
16mM thymidine) plus 0.2mM 1-(2-deoxy-2-ﬂuoro-1-
D-arabinofuranosyl)-5-iodouracil (FIAU) for 7 days,
followed by growth in HT medium (0.1mM hypoxan-
thine/16mM thymidine) for 4 days.
We screened colonies that survived selection by
Southern blotting after DNA from individual colonies
had been digested with a restriction enzyme (BamHI for
the 50-end and HindIII for the 30-end), electrophoresed on
0.7% agarose gels, and blotted onto Nylon membranes
(Hybond-N
+, Amersham Biosciences). To identify cor-
rectly targeted clones at the 50-end, we probed blots with
the 1.1-kb BamHI–SacI mouse genomic fragment
upstream of the 50-ﬂanking homology used in the targeting
vectors. For the 30-end, we used a 1.0-kb BglII–EcoRI
DNA probe, which is a subfragment of the 6.5-kb
30-ﬂanking homology used in the targeting vector. All
probes were labeled by random priming in the presence
of a-
32P-dCTP (Megaprime DNA labeling system,
Amersham Biosciences).
The Darwin Transgenic Core injected modiﬁed ES cells
into blastocysts from albino C57BL/6-Tyr
c-Brd mice (28).
We then tested chimeric males for germline transmission
by crossing them with C57BL/6-Tyr
c-Brd mice and ob-
serving coat color and genotyping by PCR (Figure 1C).
We generated homozygous HPRT-ID2-hRho-GFP
(HPRT-ID2) mice by crossing F1 progeny. We removed
the HPRT minigene in two steps. By crossing appropriate
mice, we combined the HPRT-ID2 allele with a transgene
(GDF-9-iCre) that expresses iCre from the GDF-9
promoter, which drives expression in the female germline
(29). Mice expressing the transgene were a gift from Dr
Austin J. Cooney. We then bred female HPRT-ID2/
GDF-9-iCre mice to wild-type C57Bl/6 mice to generate
mice that had eliminated the HPRT minigene. PCR
analysis of progeny identiﬁed ID2-hRho-GFP mice that
were missing the HPRT minigene and the GDF-9-iCre
transgene (Figure 1E, pup 4).
See Supplementary Data for details of mouse
genotyping and histology.
AAV-ISceI vector construction and subretinal injection
The rAAV-ISceI carries AAV2 inverted terminal repeats
in pseudotyped AAV5 capsids and expresses ISceI from
the proximal murine rod opsin promoter (from  385 to
+86), which drives expression of the recombinant gene
product almost exclusively in photoreceptors (30). We
built the plasmid precursor of rAAV-ISceI using the
pTR-MOPS500(E-)GFP vector (30). We began by insert-
ing a double-stranded oligonucleotide (50-NotI–EcoRI–
BamHI–SalI) in place of the multicloning sites between
the NotI and SalI sites in phagemid pBlueScript SKII.
We used EcoRI and BamHI to excise a 0.87-kb
fragment containing the ISceI transcription unit with the
3x nuclear localization signal from plasmid pCMV-3x nls-
ISceI (7), and subcloned it into the modiﬁed pBlueScript
SKII vector. We then digested the resulting construct with
NotI and SalI to liberate the ISceI fragment and inserted it
into the pTR-MOPS500(E-)GFP vector in place of the
existing 1.3-kb NotI–SalI fragment that encoded EGFP.
We used the resulting pTR-MOPS500-ISceI vector to
generate rAAV-ISceI (2.25 10
12 viral particles per milli-
liter) by standard procedures (30). The pTR-MOPS500
(E-)GFP vector was used to generate rAAV-GFP
(1.38 10
14 viral particles per milliliter).
For subretinal injections, we followed established pro-
cedures (31) with some modiﬁcation (Supplementary
Data). We performed subretinal injections under direct
observation via a dissecting microscope (SMZ-800 Zoom
Stero Microscope, Nikon Instruments Inc.) at  30 mag-
niﬁcation. We injected  0.7mlt o1 ml of rAAV-GFP or
rAAV-ISceI subretinally using UltraMicroPump II
(World Precision Instruments) for mice of 8–12g. After
all injections, we treated mice daily with 1% atropine
eye drops and neomycin/polymyxin B/bacitracin ophthal-
mic ointments for 3 days. At 4–27 weeks post-injection, we
prepared retinal whole mounts for examination.
Fluorescence microscopy
Retinal whole mounts were prepared 4–27 weeks after in-
jection from eyes ﬁxed in 4% paraformaldehyde, by
removing the cornea, lens and vitreous and dissecting
the retina from the eyecup. We placed the retina on a
slide with the photoreceptors up, ﬂattened it by making
radial incisions, and mounted it with Gel/Mount
(Biomeda, Foster City, CA, USA). To determine the fre-
quency of ﬂuorescent green rods, we captured multiple
images from each injected retina using an LSM 510
laser-scanning confocal microscope (Zeiss). The affected
areas of retinas, as judged by the presence of green rods,
ranged from <5% to >80% of the overall retina in differ-
ent samples; however, we quantiﬁed green rods only in the
transduced areas. For rAAV-GFP-injected controls, we
collected one retina for each time point, except the
4-week sample, for which we collected two. For
rAAV-ISceI injected mice, we examined 2–5 retinas for
the 6-, 7-, 8-, 10- and 12-week time points and one
retina each for the 4-, 5-, 18-, 19-, 24-, 26- and 27-week
time points. We examined retinas using either a  40 or a
 63 objective and a  10 eyepiece. We manually counted
all the green rods in a 50mm 50mm area of the  63
image or in the entire 230mm 230mm ﬁeld of the  40
image. We counted several different ﬁelds for each retina,
adjusted the counts to the area of the  40 image and
averaged them.
PCR analysis of DSB-repair events
We designed nested sets of primers to detect the products
of SSA and NHEJ. Primer sites and product sizes are
shown schematically in Figure 3A (see Supplementary
Data for primer sequences). PCR analysis of SSA and
NHEJ products in bulk samples is given in
Supplementary Data. For small-pool PCR analysis, we
isolated DNA from retinal whole mounts that had been
examined by confocal microscopy and shown to have a
substantial proportion of ﬂuorescent green rods. Slides
were washed in 1  PBS for 10min to loosen the cover
slip, and the mounted retinas were scooped up with a
Nucleic Acids Research, 2011,Vol.39, No. 14 5957razor blade and washed several times to remove mounting
media. We extracted DNA from the recovered retinas
using the same protocol for isolating tail DNA. We
treated individual retinas with 250mg of proteinase K in
500ml of lysis buffer containing 50mM Tris, pH 7.5,
50mM EDTA, pH 8.0, 100mM NaCl, 5mM DTT,
0.5mM spermidine and 1% SDS at 55 C overnight with
constant agitation. The lysate was then extracted once
with phenol–chloroform–isoamyl alcohol (25:24:1), and
the high-molecular weight DNA was precipitated and
spooled out by adding 0.15 volumes of 7.5M NH4OAc
and three volumes of absolute alcohol. The DNA was
rinsed successively in 70% alcohol and 100% alcohol,
and then air-dried and dissolved in 250ml TE.
To eliminate unmodiﬁed genomes from the analysis, we
digested 5mg of retinal DNA at 37 C with 30 units of
ISceI endonuclease for 3h, and then added 30 more
units of enzyme and digested the sample overnight. We
then extracted the digestion mixture once with phenol–
chloroform–isoamyl alcohol, precipitated it with alcohol,
and dissolved the pellet in TE. We then repeated this
ISceI-digestion protocol once more. Finally, we digested
this DNA with BamH1, which does not cleave within the
ampliﬁed region, to reduce viscosity and maintain consist-
ency during serial dilutions.
For small-pool PCR, we initially set up seven reactions
each at DNA concentrations of 100, 50, 25 and 12.5pg per
reaction in order to determine the optimum dilution to use
for each retina, so that each reaction contained less than
two ampliﬁable genomes on average. We used a mixture of
three PCR primers, two forward primers (P1 and P6) and
a reverse primer (P2), to amplify genomes repaired by SSA
and NHEJ (Figure 3A). Primers P1 and P2 yield a 687-bp
band for SSA products; primers P6 and P2 yield a variety
of bands near 997bp for NHEJ products, depending on
the extent of modiﬁcation at the repaired junction.
Primers P1 and P2 could potentially generate a 1.8-kb
band from NHEJ products, but we selected PCR condi-
tions that were not favorable for this long product. We
used Roche’s Expand Long Template PCR System
(Roche, Cat. No. 11 681 842 001) with buffer 2, 1.25U
of enzyme, 0.54mM dNTPs and 0.63mM for each primer,
in a ﬁnal reaction volume of 15ml. The PCR program was
94 C for 2min for initial denaturation, followed by 15
cycles of 94 C for 10s, 60 C for 30s, 68 C for 45s, then
another 15 cycles with 1s extra extension time per each
additional cycle, and one ﬁnal cycle at 68 C for 7min. We
divided the PCR products into two portions: one for
small-pool PCR analysis and the second for follow-up
ISceI digestions. For small-pool PCR analyasis, samples
were separated by electrophoresis on 1.5% TAE agarose
gels at 25V for 18h, transferred to a 0.45-mm nylon
membrane (Magnaprobe, GE Water & Process
Technologies), and hybridized with a-
32P-dCTP labeled
687-bp PCR DNA, which was generated using primer
P1 and P2 to amplify the 687-bp band from plasmid
pCR2.1-TOPO-687, which carried the SSA product. The
positions of bands were visualized by phosphorimaging.
To determine whether bands near the 997-bp marker
arose by ampliﬁcation of an NHEJ product or a genome
with an intact ISceI site, we re-ampliﬁed the portion of the
sample we had set aside, using the same conditions as
before, except in a 50-ml reaction volume and using 25
cycles of ampliﬁcation in the second step of PCR using
the nested primers P8/P3. We then digested the ampliﬁed
material with ISceI, which would cut an intact genome
into 312- and 644-bp fragments. Cutting was assessed by
electrophoresis on an agarose gel.
Analysis of individual green rods
We collected retinas from ID2-hRho-GFP mice injected
with AAV-ISceI 7–8 weeks post-injection, and dissociated
them using a modiﬁcation of a previously described
protocol (32). In brief, we pooled 2–3 injected retinas
and incubated them for a short time in a pronase
solution at 37 C. We dissociated the pronase-treated
retinas at room temperature by two cycles of 50
passages through a 1-ml pipette tip, pelleting of the
retinal fragments by centrifugation, and removal of the
supernatant for the next cycle of treatment. About
0.5ml of the combined cell suspensions was spread over
a 50-mm glass bottom dish (MatTek Corporation). We
picked individual green rods under the ﬂuorescent micro-
scope (Nikon Eclipse TE2000-U), using a motorized
micromanipulator system (MP-225, Sutter Instrument)
and a micropipette with a 5–6mm inner diameter and
30-degree bend at the tip (Origio Humagen Pipets). We
then ejected the picked green rod into a 100-ml PCR tube
(Applied Biosystems) containing 2ml of denaturing
reagents. Rhodopsin cDNA was prepared using the
QIAGEN OneStep RT-PCR kit. We ampliﬁed the
cDNA using primers to GFP and exon 1 of human rhod-
opsin. The initial product was further ampliﬁed using
nested primers within GFP and exon 1. Products were
analyzed by gel electrophoresis, with bands at 960bp
indicating mRNAs with two copies of exon 2 and bands
at 791bp indicating mRNAs with one copy of exon 2,
consistent with SSA. We sequenced the bands to verify
their structure. A detailed description of this protocol is
included in Supplementary Data.
RESULTS
The ID2-hRho-GFP mouse model
We generated mice carrying a human rhodopsin-GFP
fusion gene with a duplicated copy of exon 2
(ID2-hRho-GFP) by homologous replacement of the en-
dogenous mouse rhodopsin gene in a two-step procedure,
as outlined in Figure 1A. The targeting construct carries a
modiﬁed version of the human rhodopsin gene linked to
the sequences that ﬂank the mouse rhodopsin gene. We
modiﬁed the genomic human rhodopsin gene in three
ways. First, we fused the gene for enhanced GFP to the
C-terminus of the rhodopsin gene, so that the encoded
rhodopsin protein would be linked to GFP through the
peptide APVAT, as described previously (26). Second, we
inserted a 613-bp segment encompassing exon 2 into
intron 2 to create an internal duplication, with the two
segments separated by 564bp that include the recognition
site for the rare-cutting nuclease ISceI. The predicted
splicing pattern for the modiﬁed rhodopsin gene would
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junction between the two copies of exon 2, which would
encode a rhodopsin fragment terminating at amino acid
177 (equivalent to Y178ter). Third, at the 50 junction
between mouse and human rhodopsin sequences in the
middle of the upstream untranslated region, we inserted
a minigene encoding hypoxanthine-guanine
phosphoribosyl transferase (HPRT) ﬂanked by LoxP
sites to serve as a selectable marker for manipulation of
ES cells. Cre-mediated removal of the marker leaves
behind a single copy of LoxP, giving rise to an mRNA
that is translated  5-fold less efﬁciently than an mRNA
lacking LoxP (26). We designed this modiﬁcation to lessen
the possibility that the rhodopsin fragment made in the
parent mice might cause retinal degeneration on its own,
interfering with our assays for DSB repair. From previous
results, we knew that expression of the reduced level of
human rhodopsin-GFP (as would be generated if a DSB
were repaired by HR) would be readily detectable (26,27).
We generated modiﬁed mouse ES cells by gene targeting
(Figure 1A) and identiﬁed clones that were properly
targeted at both their 50- and 30-ends by Southern
blotting (Figure 1B). Blastocyst injection of these
modiﬁed ES cells generated chimeric mice, some of
which displayed germline transmission of the modiﬁed
human rhodopsin-GFP gene (Figure 1C). Offspring
carrying ﬂoxed HPRT in the ID2-hRho-GFP allele
(HPRT-ID2) were bred to mice with an iCre transgene
driven by the GDF-9 promoter, which is expressed in
the female germline (29), to generate mice that carried
both genes (Figure 1D, pup 1). Female HPRT-ID2/
GDF-9-iCre mice were crossed to wild-type mice and
pups were analyzed by PCR to identify those that were
missing HPRT (ID2-hRho-GFP) and that did not carry
GDF-9-iCre (Figure 1E, pup 4). These mice were bred to
homozygosity to maintain the line. For all experiments,
they were crossed to wild-type mice to generate heterozy-
gotes that carry one ID2-hRho-GFP allele and one
normal mouse allele.
To verify that the ID2-hRho-GFP allele was compatible
with the development and maintenance of a healthy retina,
which is essential for measuring frequencies of DSB repair
over time, we examined retinal sections from mice that
were heterozygous for ID2-hRho-GFP. The morphology
of ID2-hRho-GFP retinas was normal. In addition, the
number of nuclei in the outer nuclear layer at 1 month
was normal, and the rate of loss of nuclei was slight and
indistinguishable from the rate in mice that expressed
non-mutant hRho-GFP (Supplementary Figure S1).
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Figure 1. Generation of human rhodopsin-GFP mouse. (A) Strategy
for replacing the mouse rhodopsin gene with the ID2-hRho-GFP
gene. The mouse rhodopsin gene and ﬂanking sequences are shown in
dark gray, with exons indicated by rectangles and introns by lines. The
human rhodopsin–GFP fusion gene is shown in black except for the
duplicated segments containing exon 2 and the fused GFP (G) gene,
which are shown in white. LoxP sites (inverted triangles marked with P)
ﬂank the HPRT minigene (light gray), which was inserted at the
boundary between the human and mouse rhodopsin sequences. The
30 boundary between human and mouse DNA is marked by a
Lox511 site, which is not shown as it played no role in these experi-
ments. (B) Southern blot analysis of ES cells. Restriction enzymes used
to digest genomic DNA for analysis of the 50- and 30-ends of the
modiﬁed locus are shown in parentheses, and fragment sizes are
Figure 1. Continued
indicated in kilobases. (C) PCR analysis of tail DNA from HPRT-ID2
targeted mice. PCR product sizes are indicated in kb. (D) Breeding
scheme to generate mice carrying the HPRT-ID2 and GDF-9-iCre
genes. Heterozygous HPRT-ID2 mice were crossed with GDF-9-iCre
mice. Examples of mice with each of the four expected gene combin-
ations are shown. (E) Breeding scheme to remove the HPRT minigene.
A female mouse heterozygous for both the HPRT-ID2 gene and the
GDF-9-iCre transgene was crossed to a wild-type (C57BL/6) mouse.
Examples of mice with four different gene combinations are shown.
Pup 4 contains the ID2-hRho-GFP gene, but not the GDF-9-iCre
transgene or the HPRT minigene.
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able marker for experiments to detect DSB repair: neither
the mutant allele nor the corrected version is expected to
adversely affect the lifespan of rod cells.
Spontaneous reversion of the ID2 mutation
To establish a baseline against which to measure repair of
DSBs by SSA, we examined untreated retinas from
ID2-hRho-GFP mice to determine the frequency with
which the internal duplications spontaneously resolve
into a gene structure that can express hRho-GFP. We
prepared whole mounts of 27 retinas from mice at ages
ranging from 4 to 52 weeks and scanned them by ﬂuores-
cence microscopy to identify rods displaying GFP ﬂuores-
cence, referred to here as ‘green rods’. We observed a total
of 360 events, for an average of 13.3 events per retina. By
ﬂuorescence and confocal microscopy, we distinguished
three categories of event: tight groups of rods containing
from four to more than 30 green rods per cluster (28
events); doublets of rods, the minimal cluster (200
events); and single rods (132 events) (Figure 2A).
Clusters (including doublets), which account for 63% of
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Figure 2. Fluorescent green rods in retinal whole mounts from heterozygous ID2-hRho-GFP mice. (A) Confocal images of retinal whole mounts
from heterozygous ID2-hRho-GFP mice. (a) Images of clusters of green rods. (b) Image of rod doublets. As was typical of doublets, the two rods
were closely apposed and were difﬁcult to distinguish except by rotation of the projection angle through the image stacks. In this image the two rods
are slightly separated at one end. (c) Images of individual rod cells. All images were taken at the same magniﬁcation; scale bar is 10mm. (B) Confocal
images of retinal whole mounts after subretinal injection of rAAV-ISceI. For retinas expressing hRho-GFP, confocal images were captured at the
indicated times post injection using a  40 objective and a  10 eyepiece. Scale bar is 20mm. (C) Confocal images of retinal whole mounts after
subretinal injection of rAAV-GFP. For retinas expressing GFP, images were captured at the indicated times using a  63 objective and a  10
eyepiece. Scale bar is 20mm. (D) Counts of ﬂuorescent green rods after subretinal injection of rAAV-ISceI. (E) Counts of ﬂuorescent green rods after
subretinal injection of rAAV-GFP. For (D) and (E), counts are expressed as number of green rods per unit area (which corresponds to the size of the
ﬁeld observed with a  40 objective). Error bars indicate standard deviations.
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retinal progenitor cells, which divide to generate columns
of retinal neurons during differentiation of the retina
(33,34). As expected since they were generated in progeni-
tor cells, the numbers of clusters showed no age
dependence over the range of observation. Surprisingly,
however, the same was true for single rods, suggesting
that these spontaneous events may occur much more fre-
quently in terminally differentiated cells shortly after the
last cell division than at later times in the fully developed
cells. In any case, this analysis establishes that spontan-
eous green rods in the retinas of ID2-hRho-GFP mice are
rare. Given that mouse retinas contain  6.4 million rods
(35), spontaneous events that generate green rods (13.3 per
retina) occur at a frequency of  2 10
 6. This very low
frequency deﬁnes the baseline against which to compare
DSB-induced SSA events.
Repair of DSBs in the ID2-hRho-GFP gene
To induce DSBs in the target rhodopsin gene, we injected
rAAV-ISceI subretinally in 3- to 4-week old ID2-hRho-
GFP mice and followed the appearance of ﬂuorescent
green rods for several months by confocal microscopy.
Expression of passenger genes from subretinally
injected rAAV typically takes up to 3 weeks—a delay
thought to be due to the slow conversion of rAAV
DNA to a transcriptionally active, double-stranded form
in rod cells (30). As shown in Figure 2B, green rods ﬁrst
appeared at  4 weeks post-injection and continued to
increase in frequency over time. To measure the efﬁciency
of rAAV transduction, we injected rAAV-GFP and fol-
lowed appearance of rods expressing GFP (Figure 2C).
We calculated frequencies as the number of green rods
per area observed in the  40 objective ﬁeld
(230mm 230mm), which contains  23000rod photo-
receptors (35), and plotted them as shown in Figure 2D
and E. GFP expression after subretinal injection of
rAAV-GFP (Figure 2E) indicates that 22% of rods were
transduced by 6 months after treatment. At that time,
3.3% of rods expressed hRho-GFP (Figure 2D),
indicating that 3.3/22=15% of transduced rods had
been modiﬁed to express hRho-GFP. Thus, the frequency
of green rods among transduced cells is >70000-fold
above the frequency of spontaneous green rods. Because
rAAV vectors have been shown to persist and express
their passenger genes robustly for at least 6 months in
the mouse retina (36), the simplest explanation for the
plateau in the number of events seen in Figure 2D is
that by 6 months ISceI has cleaved the genome in all
the rod cells where it is expressed. Those events that
have not undergone repair by SSA have been repaired
by mutagenic NHEJ, leading to loss of the ISceI site, an
explanation conﬁrmed by the analysis of the products
presented below.
Products of ISceI-induced DSBs
We designed the ID2 target so that delivery of a DSB at
the ISceI site between the duplicated segments would
stimulate recombination via SSA, giving rise to green
rods. In addition, we expected mutagenic NHEJ to
generate alterations at the site of ISceI cleavage. To deter-
mine which of these potential products had been generated
by treatment of ID2-hRho-GFP mice with rAAV-ISceI,
we analyzed ISceI-resistant genomes, since both SSA and
NHEJ products would lack the ISceI site. Digestion with
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Figure 3. Analysis of SSA and NHEJ events. (A) Scheme for PCR
analysis of SSA and NHEJ events. The duplicated copies of exon 2
along with their ﬂanking introns are shown in white and marked by
horizontal arrows. The ISceI cleavage site is indicated by a vertical
arrow. Small numbered arrowheads indicate PCR primers. Primer
pairs and their expected PCR fragment sizes are listed beneath the
initial ID2-hRho-GFP gene and the structures of the genes resulting
from SSA- and NHEJ-mediated repair of ISceI-induced DSBs. (B)
Small-pool PCR of DNA from a single AAV-ISceI-injected retina. A
mixture of primers (P1/P6/P2) was used to amplify DNA samples, and
the PCR fragments were separated by gel electrophoresis and visualized
by Southern blotting. Size markers for products of NHEJ (997bp,
primers P6/P2) and SSA (687bp, primers P1/P2) are present in the
ﬁrst lanes of each blot. We counted bands at the position of the SSA
marker as arising from SSA events, and bands at the position of the
NHEJ marker and elsewhere as arising from NHEJ events (or back-
ground genomes with intact ISceI sites). Each distinct band was
counted once, regardless of its intensity. (C) Distinguishing NHEJ
events from background genomes with intact ISceI sites. Samples
with bands at 997bp were re-ampliﬁed with nested primers P8/P3, sub-
jected to ISceI digestion, and displayed on agarose gels. The ﬁrst lane
shows the 644- and 312-bp bands expected for digestion of a PCR
product (956bp) with an intact ISceI site. The rest of the samples are
shown in pairs, with the undigested control on the left and the
ISceI-digested sample on the right. In two instances on this gel, the
ampliﬁed sample was cleaved with ISceI; these samples were designated
ISceI
+ (Table 1).
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ISceI-sensitive genomes that come from non-rod cells
[ 22% of retinal cells (35)] and from rod cells that had
not been transduced.
We subjected DNA from treated retinas to two or three
cycles of ISceI digestion and PCR ampliﬁcation of the
region around exon 2 (Supplementary Figure S2). To
enrich for the products of SSA (Figure 3A), we used
primers P1/P2 in the initial round of ampliﬁcation and
primers P1/P3 subsequently. The 657-bp band corres-
ponding to the putative SSA product was puriﬁed from
the gel after the ﬁnal cycle and cloned (Supplementary
Figure S2). DNA sequence analysis revealed that the
cloned DNA matched the expected product of recombin-
ation between the two copies of exon 2, as illustrated
in Figure 3A. These results conﬁrm that SSA between
duplicated segments occurs in rod cells. To verify that
the genomes in green rods had structures consist-
ent with their generation by SSA, we isolated 13 indi-
vidual green rods from dissociated retinas and analyzed
their hRho-GFP mRNA by RT–PCR, using pri-
mers in exon 1 and GFP, as shown for eight rods in
Figure 4. As authenticated by DNA sequencing, rods
that expressed hRho-GFP gave a 791-bp band with one
copy of exon 2, whereas rods that did not express
hRho-GFP gave a 960-bp band with two copies of exon
2 (Figure 4).
To enrich for the products of NHEJ (Figure 3A), we
ampliﬁed ISceI-resistant DNA using primers P4/P5 in the
initial round of ampliﬁcation and primers P6/P7 subse-
quently. To ensure that we could detect the maximum
size NHEJ-induced deletions compatible with our
primers (300bp in either direction from the ISceI site),
we cloned the unfractionated ampliﬁcation products
after the last cycle of PCR. We analyzed 128 colonies by
PCR (Supplementary Figure S3). Except for the few with
apparent insertions, the PCR products from these colonies
seemed to have very minor changes in the size, with no
obvious deletions. We obtained sequences for 37 clones.
Fourteen retained the intact ISceI site, indicating that
some uncleaved genomes evaded our isolation procedure.
Among the remainder, 19 had small deletions ranging
from 1 to 13bp and four had insertions (Figure 5,
column A). The two longer insertions, which were 42
and 48bp, were derived from the inverted terminal
repeats of rAAV. The size of the deletions, the 0–3nt of
microhomology at deletion junctions, and the proportion
of insertions are all typical characteristics of NHEJ (37).
Moreover, the modiﬁcations all overlap the site at which
ISceI is predicted to introduce a DSB. These results
conﬁrm that ISceI cleaves rod cell genomes and that
NHEJ occurs in rod cells.
In principle, ISceI-treated ID2-hRho-GFP mice could
also give rise to green rods by NHEJ, if sufﬁcient DNA
sequence were deleted at the break to inactivate the
upstream or downstream copy of exon 2 (889 and
457bp, respectively). Primers P6/P7 (Figure 3A) could
have detected deletions up to 300bp on either side of the
ISceI site, but uncovered no deletions that extended
>50bp into the ﬂanking sequences. In the small-pool
PCR experiments described below, primers P6/P2 could
have detected a 600-bp deletion into the downstream
copy of exon 2, but, once again, no signiﬁcant dele-
tions were observed in more than 200 NHEJ junctions
(Figure 3B). Thus, NHEJ does not account for a signiﬁ-
cant proportion of the green rods found after ISceI
cleavage.
Relative frequencies of DSB repair by NHEJ and SSA
Although the above studies conﬁrm that DSBs can be
repaired by NHEJ and by the SSA pathway of HR in
terminally differentiated rod cells, they do not address
the issue of the relative frequencies with which these
pathways repair a DSB. To measure their relative
frequencies, we chose to use small-pool PCR to assess in-
dividual genomes. We isolated DNA from three retinal
whole mounts that displayed large areas of green rods at
10, 12 or 24 weeks after subretinal injection of rAAV-
ISceI. We extensively digested the DNA with ISceI to
cleave genomes that retained the ISceI recognition
sequence (i.e. genomes from cells that had not been trans-
duced by rAAV or had not been repaired by SSA or
NHEJ), and then diluted the resulting DNA so that
each PCR reaction contained on average fewer than two
intact genomes. We separated the PCR products
(generated by a mixture of primers P1, P2 and P6) by
gel electrophoresis, as shown in Figure 3B, and counted
the number of bands at the position of the SSA marker
(687bp, primers P1/P2) as SSA events, and the number at
the position of the NHEJ marker (997bp, primers P6/P2)
and at higher positions as presumptive NHEJ events.
Each sample with a band at the position of the NHEJ
marker was re-ampliﬁed and digested with ISceI to deter-
mine whether the band was a true NHEJ event or was
A
B
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Figure 4. Analysis of individual green rods. (A) Fluorescence micro-
graphs of an individual green rod cell being selected and removed
using a micropipette. (B) PCR ampliﬁcation of hRho-GFP cDNA
from initial RT-PCR reactions. Lane 1, 960-bp size marker for
NHEJ and background events, which contain two copies of exon 2.
Lane 2, 791-bp size marker for SSA events, which contain one copy of
exon 2. Lanes 3–10, PCR products from individual green rods. Lane
11, PCR product from control ﬂuorescent rod isolated from retina of
heterozygous hrhoG(H) mouse, which carries one copy of a wild-type
human rhodopsin-GFP fusion gene (26). Lane 12, non-ﬂuorescent
retinal cell isolated from an rAAV-ISceI injected retina. Sequencing
results conﬁrmed that samples 3 through 10 all contain a single copy
of exon 2, as expected for SSA events.
5962 Nucleic Acids Research, 2011,Vol.39, No. 14derived from an intact background genome (Figure 3C).
This analysis identiﬁed a small percentage of background
genomes, which were eliminated from further consider-
ation (Table 1). For several NHEJ events, we ampliﬁed
the DNA and analyzed it by sequencing. As expected,
bands at the position of the NHEJ marker gave small
deletions, whereas slower migrating bands yielded inser-
tions. We also reampliﬁed several bands at the position of
the SSA marker and conﬁrmed by sequencing that they
had been generated by SSA. Table 1 summarizes the data
obtained from three retinas. This analysis indicates that
NHEJ accounted for  85% of DSB-repair events,
whereas SSA accounted for  15%.
Absolute frequency of NHEJ
Ultimately, the ability to use mutagenic NHEJ (and HR)
for therapeutic genome editing depends on the overall ef-
ﬁciency with which changes can be introduced into the
retina. To measure the absolute frequency of rods with
NHEJ events, we isolated DNA from a retina 24 weeks
after injection of rAAV-ISceI (Retina A in Table 1). We
selected this retina because  60–80% had been exposed to
rAAV-ISceI, as judged by the distribution of green rods.
We ampliﬁed the DNA by PCR using primers P6/P7,
which does not distinguish between unaltered genomes
and NHEJ-induced mutant genomes (Figure 3A). The
PCR products were cloned and analyzed. Among 146
clones, we found 20 that contained NHEJ junctions
(Figure 5, column B), which corresponds to 13.7% with
a standard deviation of 3% expected from Poisson statis-
tics. Since ISceI is expressed only in rod cells, which con-
stitute 78% of retinal cells (35), the overall frequency of
rod genomes with engineered NHEJ mutations is
17.6±3.8% for the whole retina. Given the relative
frequencies of NHEJ (85% of all events that lead to loss
of the ISceI site) and SSA (15% of those events) (Table 1),
we can estimate that the overall frequency of rod genomes
with SSA events is about 17.6% 0.15/0.85=3.1% in
this retina. Making a small adjustment (dividing by
103.1%) to account for the SSA events, which were
excluded by the PCR strategy, gives absolute frequencies
for this retina of  17% of rods with NHEJ events and
 3% with SSA events.
These absolute values depend critically on the fraction
of the retina that was exposed to rAAV-ISceI, which
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Figure 5. Sequence analysis of 43 NHEJ clones. Both DNA strands for
the ISceI site are shown at the top in black with the sites of cleavage
indicated by triangles on the top and bottom strand. An adjacent
EcoRV site used in construction of the duplication is shown in gray.
For deletions and insertions, only the top strand is shown. The column
labeled A shows the results of analysis of 23 ISceI-resistant clones
isolated after the treatment described in Supplementary Figure S2.
The column labeled B shows the results of analysis of 20
ISceI-resistant clones isolated by screening a population of cloned
PCR fragments from genomic DNA that had not been pre-digested
with ISceI. The number of clones with the same sequence is shown
adjacent to the sequence. Deleted nucleotides are indicated as dots.
Junctional homologies for deletions are indicated by bold nucleotides
and have arbitrarily been shown to the right of the deleted nucleotides.
The number of inserted nucleotides is indicated above the triangles,
which indicate the place in the sequence where they were inserted.
The inserted sequences are: 1bp, A; 1bp, C; 42bp, CCC
GGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGC;
and 48bp, GTCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCA
GAGAGGGAGTGGCCA.
Table 1. Small-pool PCR analysis of injected retinas
Retina
a PCR
samples
Lanes with
no bands
b
Genomes
per
reaction
b
ISceI
+c NHEJ
d
(%)
HR
d
(%)
A1 90 15 1.8 2 76 (85) 13 (15)
A2 90 13 1.9 7 74 (84) 14 (16)
B 90 51 0.6 1 34 (83) 7 (17)
C 90 59 0.4 6 23 (82) 5 (18)
aThree different retinas were used. A1 and A2 are replicates of a single
retina.
bThe number of lanes that did not show a product was used to estimate
the average number of intact, ampliﬁable genomes per reaction, using
the Poisson distribution.
cISceI
+indicates the number of samples that had upper bands that were
cleavable with ISceI, indicating that they were not the products of
NHEJ events.
dNHEJ events equal the number of distinct bands around the 997-bp
marker, minus the number of ISceI
+ samples. HR events equal the
number of bands at the 687-bp marker. In neither case, have we
made an attempt to correct for samples that may contain two
distinct genomes that give the same size band.
Nucleic Acids Research, 2011,Vol.39, No. 14 5963varies from injection to injection. We can adjust these
values to allow comparisons between retinas by taking
into account the area exposed to rAAV-ISceI. Since
60–80% of the area of Retina A was exposed, the
adjusted frequencies per exposed portion are 21–28%
for NHEJ events and 3.8–5.0% for SSA events, with the
total frequency of ISceI-induced events in the range of
25–33% of rod cells in the exposed area. The value
calculated for SSA events is in reasonable agreement with
the frequency (3.3%) derived from the experiments shown
in Figure 2B and D, which measured frequencies in
exposed areas of the retina. In those experiments we also
estimated that  22% of rod cells were transduced. The
similar values for transduction efﬁciency (22%) and pro-
portion of modiﬁed rods in transduced areas (25–33%)
suggest that the ID2-hRho-GFP gene is cleaved in virtu-
ally all rAAV-ISceI transduced rods.
DISCUSSION
Diseases that are caused by dominant alleles—like RP due
to dominant rhodopsin mutations—present a special chal-
lenge for gene therapy (6). One cannot simply replace a
missing function by adding in a good copy of the gene, as
can be done for recessive diseases. One general therapeutic
strategy for dealing with dominant mutations is to use a
gene-speciﬁc damaging agent to knockout the defective
gene by NHEJ or to stimulate its correction by HR (38).
However, we know very little about NHEJ and HR in
terminally differentiated neurons, or about the efﬁciency
with which gene-speciﬁc damage can be induced. Using a
mouse model with an internal duplication of rhodopsin
exon 2 (ID2-hRho-GFP), we show here that mutations
can be induced in virtually 100% of transduced rod cell
neurons, with  85% due to DSB repair by NHEJ and
 15% by the SSA subpathway of HR. These results
indicate that therapeutic gene modiﬁcation in rod cells is
feasible.
In the experiments reported here, we designed a sub-
strate with an internal duplication to set up a competition
between DSB repair by NHEJ and SSA, in order to probe
the repair capabilities of rod photoreceptors. In the
absence of the duplication, as occurs in native rhodopsin
alleles, and in the absence of an HR-promoting sister
chromatid, which is lacking in terminally differentiated
cells, mutagenic NHEJ would be expected to repair virtu-
ally all DSBs. Thus, the limit to rhodopsin mutagenesis
depends on the proportion of rod cells in which DSBs can
be introduced, which depends in turn on the efﬁciency of
rod-cell transduction and on the efﬁciency of cleavage in
transduced cells. We show here that essentially all the rod
cells transduced with rAAV-ISceI acquire DSBs in the
ID2-hRho-GFP target gene. This very high-cleavage efﬁ-
ciency is likely due to the persistence of rAAV vectors,
which have been shown to express their passenger genes
robustly in the mouse retina for at least 6 months (36).
Although cleavage efﬁciency is excellent, our transduction
efﬁciency is only  25%. However, recent reports suggest
that transduction efﬁciencies can be improved using other
serotypes of AAV (39,40), an observation we have con-
ﬁrmed in our system (F. Chan, unpublished data).
The high efﬁciency of DSB repair by mutagenic NHEJ
suggests that it could serve as the basis for strategies
designed to knockout dominant rhodopsin alleles in rod
cells. The key will be to design a nuclease that can cleave
within the coding region of the rhodopsin gene. Over the
past decade substantial progress has been made in the
development of zinc-ﬁnger nucleases (ZFNs), which can
be engineered to cleave speciﬁc target genes (41). ZFNs
have proven exceptionally versatile, speciﬁc and selective
agents for introducing gene-speciﬁc DSBs into the
genomes of cultured cells and a variety of organisms
(11,38,41–45). Head-to-head comparisons with ISceI, the
gold standard for cleaving genomic DNA, have shown
that ZFNs can cut as efﬁciently as ISceI (10). By designing
a ZFN to cleave near the beginning of the rhodopsin gene,
repair of the break by NHEJ could be used to shift the
reading frame (two-thirds of the time on average) to
generate a fragmentary product. Gene knockout by
NHEJ repair of ZFN-induced DSBs has been used to
generate several mutant cell lines and organisms (41,42).
The efﬁcient DSB-induced mutagenesis we observe in rod
cells suggests that ZFN-directed gene knockout may be a
promising avenue to explore as a potential therapy for RP
patients with defective rhodopsin alleles.
It is no surprise that NHEJ is the primary mechanism
for DSB repair in terminally differentiated rod cells, as it is
in cycling mammalian cells (13). However, it is surprising
that 15% of ISceI-induced DSBs in terminally
differentiated rod neurons are repaired by the SSA
subpathway of HR. Previous studies in cycling cells have
shown that strand-invasion, the main pathway of HR,
occurs predominantly in S and G2, when the sister chro-
matid can serve as the template for repair (20,21,25,46,47).
In G1, strand invasion is blocked at the step of 50 to 30
resection of the ends, which is required to expose the
single-stranded DNA tails that are necessary for
invading an homologous duplex (13). This cell-cycle
control of end resection is exerted by cyclin-dependent
kinase (CDK), which mediates phosphorylation of CtIP
in S and G2 to activate it for end resection (23–25).
Although the strand-invasion and SSA pathways of HR
differ in their downstream events, they both begin with
end resection (13). Our studies in ID2-hRho-GFP mice
show that end resection is robust in rod cells, occurring
at 15% of DSBs. It is also extensive. To expose comple-
mentary exon-2 sequences on either side of the DSB, so
that the resulting single-stranded tails can pair by SSA to
bridge the break, requires that several hundred nucleotides
of DNA be removed from each end. Efﬁcient SSA in rod
cells indicates that end resection is not an insurmountable
barrier to the strand-invasion pathway of HR in rod cells.
These results raise the possibility that repair of DSBs by
HR, using an added non-mutant segment of DNA as a
template for repair, might also be feasible as an approach
to therapy for RP. Studies in cycling cells have shown that
DSB-induced gene correction from an added DNA
segment can occur at frequencies approaching 20% (11).
In addition, it may be possible to improve the efﬁciency of
HR-mediated gene editing in rod cells by knocking down
5964 Nucleic Acids Research, 2011,Vol.39, No. 14the activities of key NHEJ repair proteins, as has been
done in cultured cells (48–51).
In this study, we have focused on the basic parameters
of DSB repair in a speciﬁc class of neurons, the rod photo-
receptors responsible for dim-light vision. We
concentrated on these neurons because dominant rhodop-
sin mutations expressed in rod cells trigger the
neurodegenerative events that cause the most common
form of the hereditary blinding disease, RP. The highly
efﬁcient introduction of DSBs into rod cell genomes,
coupled to their repair by mutagenic NHEJ, offers a
promising approach to therapy of RP in human
patients. While our measurements focus on DSB repair
in rod photoreceptors, it is likely that the results can be
extrapolated to DSB repair capabilities in other classes of
mature neurons, which are poorly deﬁned at present (14).
Thus, this study lays the groundwork for any long-term
efforts to use DSBs to edit genomes in mature neurons.
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